Evotec SE (ETR:EVT)

Market Cap	1.08B
Revenue (ttm)	777.05M
Net Income (ttm)	-171.37M
Shares Out	177.30M
EPS (ttm)	-0.97
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	458,822
Average Volume	1,054,054
Open	6.02
Previous Close	6.08
Day's Range	5.92 - 6.09
52-Week Range	5.06 - 14.62
Beta	0.96
RSI	30.24
Earnings Date	Apr 17, 2025

About Evotec SE

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exsci...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1993
• Employees: 5,061
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: EVT

Financial Performance

In 2023, Evotec SE's revenue was 781.43 million, an increase of 3.99% compared to the previous year's 751.45 million. Losses were -83.91 million, -52.23% less than in 2022.